Full-length tissue factor (flTF), the coagulation initiator, is overexpressed in breast cancer (BrCa), but associations between flTF expression and clinical outcome remain controversial. It is currently not known whether the soluble alternatively spliced TF form (asTF) is expressed in BrCa or impacts BrCa progression. We are unique in reporting that asTF, but not flTF, strongly associates with both tumor size and grade, and induces BrCa cell proliferation by binding to β1 integrins. asTF promotes oncogenic gene expression, anchorage-independent growth and strongly up-regulates tumor expansion in a luminal BrCa model. In basal BrCa cells that constitutively express both TF isoforms, asTF blockade reduces tumor growth and proliferation in vivo.
Introduction
In breast cancer (BrCa), proteins that modulate splicing events such as ASF/SF2 and SR(Serine/Arginine-rich)p55, are frequently up-regulated and contribute to cell transformation [1, 2] . BrCa cells exhibit specific alternative splicing signatures that were proposed as potential prognostic factors in BrCa [3] . Alternative splicing of proteins such as spleen tyrosine kinase (Syk), p53, phosphatase and tensin homolog (PTEN), chemokine (C-X-C motif) receptor 3 (CXCR3) and ras-related C3 botulinum toxin substrate 1 (Rac1) impacts BrCa cell behavior and therefore, disease progression [4] [5] [6] [7] [8] .
Full-length Tissue Factor (flTF) is the principal initiator of blood coagulation [9] . Following vascular damage, flTF binds its ligand FVII(a), which triggers clot formation. Aside from sub-endothelial tissues, flTF is also abundant on cancer cells [9] and fuels tumor progression by modulating integrin α3β1 function, cell migration [10] , and fVIIadependent in Protease Activated Receptor (PAR)2 activation, but flTF-β1 integrin complexation enhances PAR2 activation [11] . flTF-dependent PAR2 activation results in the production of VEGF, CXCL1, and IL-8, thus promoting the angiogenic switch and consequently, tumor growth in vivo [10, 11] .
Alternative splicing of TF pre-mRNA results in the deletion of exon 5 and thus a frameshift in exon 6, yielding a transmembrane domain-lacking isoform that can be secreted [12] .
Cell proliferation and apoptosis assays.
Cell proliferation was assessed using MTT assays as described previously [23] . In some experiments, outcomes of MTT assays were verified using cell counting and DNA analysis. In brief, cells were seeded in 10-cm dishes, lifted, and counted at day 0 and day 3. Proliferation was expressed as an increase in cell number compared with the cell number at day 0. For DNA analysis, cells were lysed in SDS buffer at day 0 and day 3 and DNA contents were measured using Nanodrop. When appropriate, flTF-(10H10, 50 µg/ml), asTF-(RabMab1, 50 µg/ml), β1-and β3 integrin antibodies (50 µg/ml) or a β1 peptide (1 nM) were added. To measure apoptosis, cells were lifted, incubated with Annexin V/propidium iodide (both Sigma-Aldrich, St. Louis, MO) and measured by FACS (LSR2; Becton Dickinson, Franklin Lakes, NJ)
Immunofluorescence studies. For HUTS-21 staining, cells were fixed in methanol for 5 minutes. In all other experiments, cells were fixed in 2% (wt/vol) formaldehyde, permeabilized with 0.1% Triton-X100 when appropriate. Cells were incubated overnight with primary antibodies followed by incubation with secondary antibodies conjugated to Alexa-488 or Alexa-594. Coverslips were mounted using Vectashield containing DAPI (Vector Laboratories, Burlingame, CA). In some experiments, cells were incubated with fluorescently-conjugated asTF for 20 min, before fixation. Images were acquired using a Leica SP5 confocal microscope and a Leica DMI6000B.
Orthotopic breast cancer models and immunohistochemistry.
Animal experiments were approved by the animal welfare committee of the Leiden University Medical Center (LUMC). 5 animals per experimental group were used. The 2A3-3 cells (2*10 6 in 50 µl) were injected into the inguinal fat pad of NOD-SCID mice (Charles River, Wilmington, MA). Tumor growth was measured using calipers and the formula Volume=(length*width*width)/2. For MDA-MB-231-mfp growth in vivo, 0.5*10 6 cells were injected in fat pads of NOD-SCID-gamma mice (Charles River). After completion of the experiment, mice were killed and tumors were extracted and fixed in 4% formalin. Sections were de-paraffinized, rehydrated and endogenous peroxidase activity was blocked with 0.3% H 2 O 2 . Antigen retrieval was done in sodium citrate buffer for 10 minutes at 100˚C. Sections were blocked with 10% normal goat serum in PBS and incubated overnight at 4 ˚C with primary antibody. Sections were incubated for 30 minutes with Envision (Dako, Heverlee, Belgium), visualized using DAB, and counterstained with hematoxylin.
Tissue microarray analysis.
A tissue array was constructed from tumor material obtained from 574 non-metastasized breast cancer patients that mostly underwent tumor resection at Leiden University Medical Center between 1985 and 1994 [24] . Approval was obtained from the LUMC Medical Ethics Committee. Age, tumor grade, histological type, tumor-node-metastasis status, median follow-up (17.9y), locoregional or distant tumor recurrence, and expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) were known. Tumors were graded according to the current pathological standards. Normal mammary tissue of 266 patients (46%) was available for analysis. Sections were cut and stained for flTF and asTF as described above. The percentage of asTF and flTF positive tumor cells was scored by two blinded observers. Patients in the 1 st quartiles were deemed negative.
Statistics.
Assessment of the associations between flTF/asTF expression and clinical variables were performed using SPSS and Stata. Cohen's κ coefficient for inter-observer agreement was 0.85 and 0.88 for asTF and flTF, respectively. The χ² test was used to evaluate associations between clinicopathological parameters and asTF/flTF expression. Analysis of in vitro and in vivo experiments was carried out using t-tests. Mean and SD are shown in figures, unless stated otherwise. Significant differences in bar graphs are indicated by * (p<0.05), ** (p,0.01) and *** (p,0.001).
Results asTF expression positively correlates with BrCa grade and stage
Prior studies pointed to a potentiating role for TF in tumor progression [19, 20, 25] . To explore whether asTF and flTF differentially contribute to BrCa progression, we analyzed asTF and flTF protein expression in a BrCa tissue array comprising specimens from 574 BrCa patients [24] . asTF and flTF were detectable in >95% of the BrCa specimens with various degree of tumor cell positivity. Healthy mammary tissue showed far more limited expression of asTF compared with flTF (asTF: 4% of all specimens, flTF: 38%; Fig. S1A ). Specificity of previously validated flTF-and asTF-specific antibodies [21] was re-confirmed (Fig. S1B) . Confocal analysis revealed flTF localization on the cell membrane, while asTF was mostly intracellular (Fig. S1C) .
Expression of asTF positively correlated with histological grade as well as tumor size (Table  I) , but flTF expression only correlated with grade. asTF expression also correlated with age. No significant associations were found between asTF or flTF levels and estrogen receptor (ER), progresterone receptor (PgR), or human epidermal growth factor receptor 2 (HER2) status. This finding raises the possibility that asTF impacts BrCa progression in a manner qualitatively distinct from that of flTF.
asTF expression enhances proliferation of BrCa cells
To explore the mechanistic link between the unique correlation of asTF expression and BrCa clinical parameters, we constructed MCF-7 cells harboring a genomic flippase recognition target (FRT) insertion, thus containing a unique locus-specific DNA acceptor site and established several FRT lines, selecting clone 2A3-3 for further studies. Insertion of asTF and flTF cDNA resulted in similar mRNA expression levels, but intracellular protein levels of asTF were lower (Fig. S2A, S2B ), likely because of asTF secretion (see below and Fig. 1G ). Confocal analysis revealed that flTF was localized on the plasma membrane, confirmed by FACS analysis (Fig. S2D ), but asTF was present in vesicular structures (Fig.  1A) . Only 2A3-3 flTF exhibited significant coagulant activity (Fig. S2C) . asTF protein levels were ~ fivefold higher in 2A3-3-asTF cell lysates than in lysates of tumor tissue-array specimens with high asTF positivity, likely because of the constitutive asTF overexpression of 2A3-3 cells and the appreciable presence of asTF-negative stroma (upto 50%) in our tumor specimens (Fig. S2E) . The 2A3-3 cells expressing flTF, asTF, an aspecific protein (β-Galactosidase), or empty vector control cells (pcDNA) were tested in an MTT proliferation assay and compared with parental MCF-7 cells. The 2A3-3-pcDNA and 2A3-3-βGal proliferation rates were identical to those of MCF-7 (Fig. 1B) , but proliferation rates of 2A3-3-asTF cells were increased by ≥twofold, while those of 2A3-3-flTF cells were only modestly increased. Cell counting and genomic DNA measurements confirmed these results (Fig. S3A, S3B ). An independently established second 2A3-3-asTF line showed similar proliferation rates (Fig. S3C ) and TF-specific shRNA eliminated enhanced proliferation (Fig. 1C,D) , confirming that the effect was asTF-dependent. Because asTF contains an unusual C terminus as a result of a frameshift, a possibility exists that asTF expression may increase cell proliferation through activation of the unfolded protein response. However, we found no evidence for unfolded protein response activation or protein aggregation, neither in flTF-nor in asTF-expressing cells (Fig. S3D, S3E ). Increased cell numbers were also not a result of increased cell survival, as all cell lines exhibited similar viability levels (Fig. S3F ).
asTF and flTF expression resulted in down-regulation of cell cycle inhibitors and enhanced phosphorylation of the pro-mitogenic p42/p44 MAP kinase (Fig. 1E) . Effects of flTF and asTF expression on proliferation were somewhat less pronounced in an MCF-7 FRT clone (2A1-2) with lower flTF/asTF expression (Fig. 1F,G and Fig. S3G ). The 2A1-2 cells exhibited decreased asTF secretion but intracellular asTF levels were equal to those in 2A3-3 cells (Fig. 1G) , suggesting that asTF secretion is important to the enhancement of proliferation. Indeed, co-culture of control cells with asTF-expressing cells increased the proliferation of control cells (Fig. 1H) . Culturing control cells in 2A3-3-asTF-conditioned medium enhanced proliferation, and asTF depletion from the medium reversed this effect (Fig. S4A) . Addition of recombinant asTF to pcDNA cells increased proliferation at concentrations as low as 1nM, well below asTF concentrations detectable in the plasma of metastatic breast cancer patients (Fig. S4B, S4C) . Incubation of asTF-expressing 2A3-3 cells with an asTF-blocking antibody, but not with an flTF-blocking antibody, reduced asTF-dependent cell proliferation (Fig. 1I) . Limited flTF-elicited proliferation was not dependent on PAR2 activation, as incubation with PAR2, as incubation with PAR2-and FVII-blocking antibodies was without effect (Fig. S4D ). These results demonstrate that secreted asTF enhances BrCa cell proliferation in an autocrine fashion. (Fig. 2A,B and Table S1 ). Expression of SRSF protein kinase 2 (SRPK2), which activates the TF pre-mRNA splicing regulator ASF/SF2 [26] , was altered by asTF and flTF, suggesting that TF splice variants may regulate their own expression. These results indicate that asTF enhances BrCa cell proliferation via modulation of cell cycle regulators, proliferation inducers, and tumor suppressors/pro-apoptotic proteins.
asTF enhances proliferation by binding to β1 integrins
Because asTF induces angiogenesis via binding integrins on endothelial cells [16] , we reasoned that asTF-dependent BrCa cell proliferation may also be integrin-dependent. Silencing of the β1 integrin subunit resulted in diminished proliferation of 2A3-3-asTF cells ( Fig. 3A and Fig. S5A ) and flTF cells (Fig. S5A, S5B ), but not 2A3-3-pcDNA cells; shRNA silencing of the β3 integrin subunit, which is not expressed in these cells, was without effect (Fig. S5C ).
Artificially truncated recombinant flTF ("sTF") was recently found to induce EC proliferation by binding to the integrin β1 region between aminoacid residues 579 and 799 [27] . Because sTF contains the entire N-terminal region of asTF, we tested whether asTF binds to this integrin region. A β1 579-799 aa domain specific antibody and a peptide mimicking this domain inhibited proliferation of 2A3-3-asTF , but not control cells or 2A3-3-flTF cells even after prolonged incubation (Fig. S5D, S5E ). Co-immunoprecipitation (IP) demonstrated that asTF directly binds to β1 integrin and binding was lost after preincubation with the β1 579-799 aa antibody (Fig. 3B) . Binding of asTF to β1 integrins was confirmed using a modified ELISA showing that asTF binds well to recombinant α6β1 (Fig. S5F ) which is consistent with our earlier findings [16] . Pre-incubation of control cells in suspension with recombinant asTF enhanced cell binding to collagen and fibronectin, but not vitronectin (Fig. S5G) , indicating that asTF binding may modulate integrin activation. Functional blockade of β1 reversed this effect (Fig. 3C) . In support of an activating effect of asTF on β1 integrins, reactivity of HUTS-21, an antibody that recognizes the active conformation of β1 integrins, increased when 2A3-3 cells expressed asTF or were exposed to recombinant asTF (Fig. 3D ). To ascertain asTF co-localization with β1 integrins, we pre-incubated pcDNA cells with fluorescently-tagged asTF; partial colocalized with β1 integrins on the cell surface was observed (Fig. S5H) . Because β1 integrin blockade in 2A3-3 cells only partially inhibited asTF-dependent proliferation, these results suggest that, aside from β1 integrins, asTF likely binds to other membrane-associated proteins.
asTF induces anchorage-independence and tumor growth in vivo
We next investigated the effects of asTF expression on oncogenic potential using soft-agar assays. Although, asTF did not affect the number of colonies, it caused a threefold increase in colony size; the impact of flTF expression on colony size was marginal (Fig. 4A,  4B ).
asTF-dependent tumor growth was then assessed orthotopically. asTF expression increased tumor expansion (Fig. 4C ), but flTF-expressing 2A3-3 cells yielded tumors that were similar in size or smaller than those formed by control cells. asTF-expressing cells yielded large tumors with little stroma, whereas control and flTF cells gave rise to small tumor islands surrounded by stroma (Fig. S6 ). flTF and asTF protein expression was confirmed in tumors in vivo, ruling out that poor growth of flTF-expressing cells was because of loss of flTF expression (Fig. S6) . asTF-expressing tumors had more CD31+ capillaries and macrophage infiltrate, and contained more proliferating tumor cells, specifically at the tumor periphery (Fig. 4D, 4E ). These data demonstrate that asTF promotes BrCa cell proliferation in vitro and in vivo.
asTF blockade reduces growth of BrCa cells expressing endogenous asTF
Although we dissected the role of asTF in tumor growth using MCF-7 cells constructed to express either asTF or flTF, native asTF is co-expressed with flTF. Moreover, MCF-7 cells express low levels of PAR2, which may mechanistically explain the lack of 2A3-3-flTFdependent tumor expansion in vivo. Because MDA-MB-231 BrCa cells express high levels of flTF and PAR2 [11] , we used them to assess the role of asTF in an flTF/PAR2-positive setting. Although asTF levels in MDA-MB-231 cells were low (Fig. 5A) , a more aggressive MDA-MB-231 sub-line that had been isolated from the mammary fat pad following orthotopic implantation (MDA-MB-231-mfp) [28] had significantly higher asTF levels, but flTF levels were unchanged. In agreement, spliceosomal proteins that promote biosynthesis of asTF mRNA were upregulated in MDA-MB-231-mfp cells (Fig. S7A) . Importantly, asTF levels in these cells were lower or equal to the asTF levels in BrCa specimens (Fig. S2E) . asTF-specific antibody blockade significantly inhibited proliferation of MDA-MB-231-mfp cells (Fig. 5B) , but had no effect on proliferation of the parental MDA-MB-231 line, demonstrating functional specificity. Selective anti-flTF antibody 10H10 did not inhibit proliferation of either cell type in vitro, which is consistent with the notion that flTF potentiates angiogenesis -but not proliferation -in these cells [11] (Fig. 5B) . A β1 integrin-blocking antibody and the 579-799 aa integrin peptide also inhibited proliferation of MDA-MB-231-mfp cells, but did not further reduce proliferation in the presence of the anti-asTF antibody (Fig. 5C ), confirming that asTF augments proliferation in MDA-MB-231-mfp via β1 integrins. The β3 integrin blockade was without effect (Fig.  5D ).
We then implanted MDA-MB-231-mfp cells orthotopically in NOD-SCID gamma (NSG) mice in the presence or absence of asTF-blocking antibody. asTF blockade with as little as 100 µg antibody significantly inhibited tumor growth (Fig. 5E ) and resulted in a marked reduction of the proliferation zone at the tumor periphery ( Fig. 5F and Fig. S7B) . Notably, asTF blockade did not reduce vascular density, suggesting that asTF does not impact angiogenesis in a model featuring a pro-angiogenic flTF-PAR2 axis (Fig. 5G, and Fig. S7B ). Thus, asTF blockade decreases the tumorigenic potential of BrCa cells expressing native asTF, flTF, and PAR2.
Discussion
Until now, contributions of asTF to tumor progression have remained unclear. This study is unique in reporting: i) asTF's selective abundance in BrCa tissue; ii) asTF-dependent, autocrine augmentation of BrCa cell proliferation; and iii )the efficacy of anti-asTf monoclonal antibodies in stemming BrCa growth. Analysis BrCa specimens from 574 patients revealed that asTF positively correlates with both grade and the T-status of cancer lesions, as well as the patients' age, but flTF correlates solely with tumor grade, and is detectable in ~40% of normal breast tissue, compared with ~4% for asTF. We demonstrate herein that asTF up-regulates BrCa cell proliferation irrespective of its impact on angiogenesis in an asTF overexpression model, as well as in BrCa cells that express native asTF.In contrast to asTF-triggered proliferation, flTF-triggered proliferation rates were low in our TF overexpressing cells. Furthermore, flTF-dependent proliferation was not observed in an aggressive MDA-MB-231 cell line that expresses asTF. Thus, asTF appears to be the major TF variant that promotes BrCa cell proliferation.
asTF upregulated genes that play pivotal roles in cell cycle progression and proliferation. CNNA1 and CNNA2, important regulators of cyclin-dependent kinases during S phase, and anaphase promoting complex 10 (ANAPC10) were significantly up-regulated in 2A3-3-asTF cells compared with control or flTF expressing cells. Growth factors [MDK, GAL and tissue inhibitor of metalloproteinases 1(TIMP1)] were also up-regulated. Alhough we observed up-regulation of some cell survival genes, we found no evidence for altered cell survival in asTF-expressing cells. Still, it cannot be ruled out that these genes contribute to the cumulative impact of asTF expression on tumor xenografts.
Our studies further revealed that asTF-integrin interactions were responsible for increased proliferation of BrCa cells. asTF co-localized with and bound to β1 integrins and β1 integrin silencing reversed asTF dependent proliferation. Anantibody against the β1 region encompassing residues 579-799 or a peptide mimicking this domain, reversed asTFdependent -but not flTF-dependent -proliferation, indicating that asTF binds to this distinct β1 region. We hypothesize that asTF induces a conformational change in β1 integrins that render them prone to activation, as we used a β1 integrin-blocking antibody that is reactive with the membrane-proximal β-tail domain (βTD) of the β1 integrin subunit, and the 579-799 integrin peptide features this domain. The βTD contains a CDloop that contacts the ligand-binding integrin βA domain and the hybrid domain, and this contact is lost upon integrin activation [29, 30] . It has been postulated that the CD-loop acts as a deadbolt, preventing integrin activation by locking βA in an inactive state. Indeed, a number of antibodies that activate β1 integrins bind to the βTD or the βA interface, and the βTD has been shown to regulate ligand binding [29, 31] . We propose that asTF induces removal of the CD-loop deadbolt. However, direct conformational effects of asTF on of β1 integrin function may not be the sole means by which asTF modulates the "integrin profile" of BrCa cells: asTF expression also up-regulates kindlin-2, a positive regulator of talin-induced integrin activation [32] , and suppresses tensin-3, a negative regulator of integrin function [33] .
The in vitro phenotype of asTF-expressing 2A3-3 cells, (enhanced proliferation and colony growth in soft agar colony growth), was recapitulated in vivo but flTF-expressing cells that proliferated only moderately faster than control cells in vitro, produced tumors of the same size as control cells. It is not clear why flTF overexpression in MCF-7 cells did not enhance tumor growth in vivo, but the paucity of PAR2 expression may be a contributing factor. PAR2 is instrumental in flTF-dependent tumor angiogenesis [11] , and poor expansion of these cells may result from a lack of PAR2-dependent angiogenesis. This finding is in agreement with the results of in vivo experiments using PAR2-expressing MDA-MB-231-mfp cells: asTF blockade did not affect vascular development in tumor xenografts, although we did not directly test the influence of asTF-induced angiogenesis on BrCa growth. Our results indicate that asTF does not significantly influence angiogenesis in the MDA-MB-231-mfp xenograft model, while upregulation of CD31+ vessels in asTF-expressing 2A3-3 tumors suggests that asTF-dependent angiogenesis may be a contributing factor in 2A3-3 xenografts. Differences in secreted asTF levels and presence of a functional flTF-PAR2 axis in MDA-MB-231-mfp cells may explain why asTF differently affects vascular density in these two xenograft models.
Alternative splicing has been deemed critical to the proliferation of BrCa cells: overexpression of ASF/SF2, a major SR protein and regulator of the flTF/asTF mRNA ratio in monocytes [18] , leads to enhanced proliferation, transformation, and BrCa growth in vivo [1] . Furthermore, the expression of SRp40 -the spliceosomal protein that promotes asTF synthesis [17] , the levels of which are up-regulated in MDA-MB-231-mfp cells -is increased in human BrCa, and associated with lymph node metastasis [34] . It may be of interest to investigate whether the effects of heightened SRp40 expression in BrCa are in part dependent on asTF production.
In conclusion, autocrine asTF expression induces integrin-mediated BrCa cell proliferation that contributes to tumor growth, rendering asTF a unique target for anti-cancer strategies that modulate the biological activity of this minimally coagulant TF form, thereby avoiding adverse impacts on hemostasis. Table I . Association of asTF and flTF with patient and tumor characteristics *During specimen processing, some tumor punches were lost leading to a smaller patient number per staining. Pvalues were calculated based on the remaining specimens. **HER2 status was not known for all patients Abbreviations: asTF, alternatively spliced tissue factor; flTF, full length tissue factor; T, tumor; N, Axillary lymph node; ER, estrogen receptor; PgR, progesterone receptor; Her2, human epidermal growth factor 2. integrins (residues 579-799) β3 integrins, or a peptide representing integrin β1 residues 579-799. (E) Proliferation was assessed after the days indicated as described. 2A3-3-pcDNA cells (circles), -flTF cells (diamonds), or -asTF cells (squares) were incubated with a β1 peptide resembling the β1 integrin region between residues 579-799 (1 nM). Proliferation was followed as in A. (F) The 96-wells plates were coated with asTF. Truncated flTF (sTF) coating was included as a positive control, as flTF was previously shown to bind to α6β1 integrins. Subsequently, the plates were incubated with the indicated recombinant integrin dimers, and bound integrin was detected using β1 antibody Ts2/16-HRP conjugated anti-mouse secondary antibody and colometric substrate (TMB). (G) 2A3-3-pcDNA cells were pre-incubated with 10nM recombinant asTF and seeded on collagen I, fibronection or vitronectin pre-coated dishes (all 10µg/ml) and left to adhere for 60 min. in Hepes-tyrode buffer. After washing, the remaining cells were counted.(H) pcDNA cells were grown on coverslips and incubated with 10 nM recombinant asTF conjugated to Alexa 594 for 20 minutes at ambient temperature. After fixation, cells were labeled with β1 antibody AIIB2 (green). Arrows indicate areas of extensive colocalization. Scale bar: 50 µm *P<0.05, **P<0.01, ***P<0.001
. Table S2 . Primer pairs used in SYBR-Green based real-time PCR.Primer sequences are from 5' to 3'. LCP1, lymphocyte cytosolic protein 1; FERMT2, fermitin family homolog 2; MDK, midkine; MSLN, mesothelin; CDH18, cadherin 18; EFEMP1, EGF containing fibulin-like extracellular matrix protein; DRAM1, DNA-damage regulated autophagy modulator 1; FAM5c, family with sequence similarity 5, member C.
